Joint Health clinical trials

Explore recruiting joint health clinical trials.

Recruiting joint health studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Joint Health trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An 18-month low-interventional prospective, multicentre study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

Hungary, Ireland, Czechia, Italy, Croatia, Spain +4 more

Therapeutic use (Phase IV) EU CTIS Study details

A Phase I/IIb extension study assessing the long-term safety and efficacy of an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.

Netherlands, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A low-interventional study to evaluate long-term effectiveness of real-world prophylactic treatment with efanesoctocog alfa on joint health in people with haemophilia A (ALTITUDE)

France, Sweden, Spain, Ireland, Czechia, Germany +2 more

Therapeutic use (Phase IV) EU CTIS Study details

A Multicenter, Open-Label Phase IV Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes, in Participants Aged ≥13 and < 70 Years with Severe or Moderate Hemophilia a Without FVIII Inhibitors on Emicizumab Prophylaxis

Italy, Spain, Hungary, Germany

Therapeutic use (Phase IV) EU CTIS Study details

A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients with Mild or Moderate Hemophilia A without FVIII Inhibitors

Germany, France, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 3b open-label, multicenter study evaluating physical activity and joint health in previously treated patients ≥12 years of age with severe haemophilia A treated with intravenous recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; efanesoctocog alfa) for 24 months

Croatia, Norway, Italy, Czechia, France, Sweden +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Joint Health trials by city

Joint Health in Toronto Joint Health in Vancouver Joint Health in Montreal Joint Health in Calgary Joint Health in Edmonton Joint Health in Ottawa Joint Health in Winnipeg Joint Health in Quebec City Joint Health in Hamilton Joint Health in Kitchener Joint Health in London Joint Health in Halifax Joint Health in New York Joint Health in Los Angeles Joint Health in Chicago Joint Health in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease